Factor V Leiden News and Research

RSS

Study offers new insight into increased risk of blood clots in women

New research from Queen Mary University of London, published in iScience, shows an increased risk of blood clots in women who have any combination of a particular gene mutation, estrogen use, or common medical conditions - specifically: obesity, high blood pressure, high cholesterol, and kidney disease.

19 Sep 2023

Clinical determinants of post-COVID-19 thromboembolism

Researchers quantify the risk of acute VTE due to SARS-CoV-2 infection in ambulatory settings.

27 Mar 2022

Anticardiolipin antibodies and COVID-19

A new study has shown that anticardiolipin antibodies are associated with the novel coronavirus infection or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19.

10 Jun 2020

Genetic susceptibility could help identify breast cancer patients at risk of developing VTE

Genetic testing could help identify breast cancer patients with high risk of experiencing venous thromboembolism (VTE), a serious and potentially fatal complication that can occur during cancer treatment.

2 Nov 2016

African Americans with common genetic variants at increased risk for blood clots

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), identifies common genetic variants predominantly found in African Americans that double their risk for blood clots.

18 Feb 2016

Sequenom's total revenues increase 62% to $39.8 million in Q2 2014

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $39.8 million for the second quarter of 2014, an increase of 62% compared to revenues of $24.5 million for the second quarter of 2013.

From Quest Diagnostics 29 Jul 2014

Blood type, blood protein mutations influence thromboembolism risk

Findings from two Danish studies have shown that ABO blood type, both alone and in combination with the presence of factor V and prothrombin mutations, is associated with increases in risk for venous thromboembolism.

20 Feb 2013

Non-O blood type - the most important risk factor for venous thromboembolism

The non-O ABO blood type is the most important risk factor for venous thromboembolism (blood clots in veins), making up 20% of attributable risk for the condition, according to a new study in CMAJ (Canadian Medical Association Journal).

6 Feb 2013

Hypercoagulable markers identified in upper arm thrombosis patients

Coagulation tests are warranted in young women undergoing surgery for subclavian vein thrombosis, especially patients with Paget-Schroetter syndrome unrelated to physical activity, say US clinicians.

17 Jan 2013

Low blood anticoagulant levels increase risk for VTE

Low plasma levels of antithrombin, protein C, and protein S significantly increase the risk for venous thromboembolism, Italian research shows.

25 Jul 2012

Women can have successful pregnancy after recurrent miscarriage

In a subset of the ALIFE study, which investigated the effect of aspirin alone or combined with low-molecular-weight heparin, compared to placebo, on the live birth rate in women with unexplained RM, the researchers looked at the length of time between the moment of randomisation to the moment of the first day of last menstruation before the subsequent pregnancy.

4 Jul 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis - the formation of often dangerous blood clots that can lead to venous occlusion.

7 Jun 2011

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

Genetic testing for inherited blood-clotting abnormalities is not routinely recommended for patients with venous thromboembolism (VTE) of unknown cause, according to a new expert panel statement in a recent issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics (ACMG).

11 Feb 2011

Risk, incidence of VTE differs between races

A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published today in the American Journal of Hematology.

24 Jun 2010

FVL gene mutation increases risk of blood clots in breast cancer patients treated with tamoxifen: Study

Women who develop blood clots while taking tamoxifen for early-stage breast cancer are more likely to carry a faulty version of a gene involved in clotting than those who do not develop blood clots, a US study has found.

18 Jun 2010

FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II

Illumina, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the VeraCode® Genotyping Test for Factor V (Leiden) and Factor II (Prothrombin).

From Illumina, Inc. 19 May 2010

FDA clears Osmetech's eSensor Thrombophilia Risk Test

Osmetech, plc today announced that the US Food and Drug Administration (FDA) has cleared the eSensor® Thrombophilia Risk Test (TRT), a multiplexed molecular diagnostic test for four genetic markers associated with thrombosis. The panel includes Factor V Leiden, Factor II Prothrombin, MTHFR 677 and MTHFR 1298 in a single test panel.

26 Apr 2010

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

7 Apr 2010

Cepheid receives approval to market Xpert(R) HemosIL(R) FII & FV test

Cepheid and Instrumentation Laboratory (IL) today announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to market its Xpert(R) HemosIL(R) FII & FV test.

25 Sep 2009

Abdominal venous thrombosis risk factors

Abdominal venous thrombosis may present as BCS or SVT. Hereditary and acquired risk factors have been implicated in the etiopathogenesis of abdominal venous thrombosis.

12 Oct 2008